Quantinno Capital Management LP Reduces Holdings in Integra LifeSciences Holdings Corporation $IART

Quantinno Capital Management LP decreased its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 45.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 459,429 shares of the life sciences company’s stock after selling 382,663 shares during the period. Quantinno Capital Management LP owned approximately 0.59% of Integra LifeSciences worth $4,328,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of IART. Paradigm Capital Management Inc. NY lifted its holdings in Integra LifeSciences by 50.6% in the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after buying an additional 1,347,700 shares during the period. Sei Investments Co. grew its holdings in shares of Integra LifeSciences by 58.4% during the 1st quarter. Sei Investments Co. now owns 93,726 shares of the life sciences company’s stock worth $883,000 after acquiring an additional 34,540 shares during the period. Walleye Capital LLC grew its holdings in shares of Integra LifeSciences by 202.0% during the 1st quarter. Walleye Capital LLC now owns 218,595 shares of the life sciences company’s stock worth $2,059,000 after acquiring an additional 146,203 shares during the period. State of Wyoming raised its position in shares of Integra LifeSciences by 26.4% in the 1st quarter. State of Wyoming now owns 25,276 shares of the life sciences company’s stock worth $238,000 after acquiring an additional 5,278 shares in the last quarter. Finally, Calamos Wealth Management LLC bought a new position in shares of Integra LifeSciences in the 1st quarter worth approximately $284,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Wall Street Zen cut Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Truist Financial raised their price objective on Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. UBS Group started coverage on shares of Integra LifeSciences in a report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price on the stock. Wells Fargo & Company increased their price target on shares of Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Finally, Weiss Ratings cut shares of Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $18.86.

Integra LifeSciences Trading Up 0.9%

NASDAQ IART opened at $17.25 on Friday. Integra LifeSciences Holdings Corporation has a 12 month low of $8.70 and a 12 month high of $20.49. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. The stock’s fifty day moving average price is $17.90 and its 200-day moving average price is $13.64. The stock has a market cap of $1.34 billion, a P/E ratio of -191.65, a P/E/G ratio of 1.44 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The firm had revenue of $418.76 million during the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.